Search

Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe

Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.

Read more

Highlights from the SWG

SWG Session at EHA2023ELN-EHA SWG for CML: CML: modelling the futureChairJane Apperley (United Kingdom)

Topics and presenters
Identifying new targets for BCR::ABL1 inhibition: Oliver Hantschel (Germany). Dissecting phylogenetic trees in CML: Aleksandra Kamizela (United Kingdom).

Read more

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes

Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has been linked to aggressive disease and patient survival of only…

Read more

International Call to Action to Alleviate Drug Shortages

The common call to action seeks first to raise awareness of shortages of drugs among hematologists.

Read more

Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.

 

Abstract S722
Acute lymphoblastic leukemia  (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.

Read more

Meet YoungEHA leaders Verena and Heiko

By Dr. Fabienne Lucas, MD PhD, YoungEHA Committee.

Read more

BENIGN HEMATOLOGY in 2023 and beyond

The term "benign hematology" has traditionally been used to refer to non-malignant blood disorders. However, over the past few years, questions have been raised as to the appropriate nomenclature for this category of diseases.

Read more